Skip to Content

Trulicity Side Effects

Generic Name: dulaglutide

Note: This page contains side effects data for the generic drug dulaglutide. It is possible that some of the dosage forms included below may not apply to the brand name Trulicity.

In Summary

Common side effects of Trulicity include: diarrhea, frequent bowel movements, nausea, and retching. Other side effects include: abdominal distress, abdominal pain, abdominal tenderness, dyspepsia, fatigue, gastrointestinal pain, lower abdominal pain, upper abdominal pain, weakness, decreased appetite, and malaise. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to dulaglutide: subcutaneous solution

As well as its needed effects, dulaglutide (the active ingredient contained in Trulicity) may cause unwanted side effects that require medical attention.

Major Side Effects

If any of the following side effects occur while taking dulaglutide, check with your doctor immediately:

Incidence not known:
  • Agitation
  • change in urination
  • chills
  • cold sweats
  • confusion
  • cool, pale skin
  • depression
  • difficulty with breathing or swallowing
  • dizziness
  • fast heartbeat
  • fever
  • hives
  • hoarseness
  • hostility
  • increased hunger
  • irritability
  • lethargy
  • loss of appetite
  • lump in the neck
  • muscle twitching
  • pains in the stomach, side, or abdomen, possibly radiating to the back
  • rapid weight gain
  • reddening of the skin, especially around the ears
  • seizures
  • shakiness
  • slurred speech
  • swelling of the eyes or inside of the nose
  • swelling of the face, ankles, or hands
  • trouble breathing
  • unusual tiredness or weakness
  • vomiting
  • yellow eyes or skin

Minor Side Effects

Some dulaglutide side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

More common:
  • Diarrhea
Less common:
  • Acid or sour stomach
  • belching
  • decreased appetite
  • general feeling of discomfort or illness
  • heartburn or indigestion
  • lack or loss of strength
  • stomach discomfort, upset, or pain
Rare
  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

For Healthcare Professionals

Applies to dulaglutide: subcutaneous solution

General

The most common adverse reactions included nausea, diarrhea, vomiting, abdominal pain, and decreased appetite.[Ref]

Gastrointestinal

Very common (10% or more): Nausea (up to 21.1%), diarrhea (up to 13.7%), vomiting (up to 11.5%)
Common (1% to 10%): Abdominal pain, dyspepsia, constipation, flatulence, abdominal distention, gastroesophageal reflux disease, eructation, lipase and/or pancreatic amylase increases from baseline (up to 20%)
Frequency not reported: Pancreatitis[Ref]

During clinical trials, a greater number of pancreatitis related adverse reactions were reported in patients exposed to this drug versus non-incretin comparators (12 cases vs 3 cases). Analyses of adjudicated events revealed 5 cases of confirmed pancreatitis in dulaglutide-exposed patients compared with 1 case in the non-incretin comparator group.

Gastrointestinal events occurred more frequently with the higher dose. Cases were graded as mild, moderate, or severe in 58% and 48%, 35% and 43%, and 7% and 11%, of patients receiving the 0.75 mg dose and the 1.5 mg dose, respectively. The severity of events was graded by clinical trial investigators.[Ref]

Oncologic

One case of Medullary Thyroid Carcinoma (MTC) has been reported in a patient treated with this drug. Prior to receiving treatment, this patient had calcitonin levels approximately 8 times the upper limit of normal.[Ref]

Very rare (less than 0.01%): Medullary Thyroid Carcinoma[Ref]

Metabolic

Very common (10% or more): Hypoglycemia (up to 85% when combined with prandial insulin)
Common (1% to 10%): Decreased appetite[Ref]

Hypoglycemia occurred more frequently when this drug was used in combination with a sulfonylurea or insulin. In combination with prandial insulin, hypoglycemia occurred in 85% and 80% of patients receiving 0.75 mg and 1.5 mg; severe hypoglycemia in 2.4% and 3.4% of patients, respectively. In combination with a sulfonylurea, symptomatic hypoglycemia occurred in 39% and 40%. As add-on therapy to metformin or metformin plus pioglitazone, symptomatic hypoglycemia occurred in up to 5.6% of patients, with no reports of severe hypoglycemia.[Ref]

Cardiovascular

During clinical trials, a mean increase in heart rate of 2 to 4 beats per minute was observed. Sinus tachycardia was reported in 2.8% and 5.6% of patients receiving 0.75 mg and 1.5 mg of dulaglutide (the active ingredient contained in Trulicity) compared with 3% in placebo. Persistent sinus tachycardia defined as occurring at more than 2 visits was reported in 0.4%, 1.6%, and 0.2% of patients receiving dulaglutide 0.75 mg, 1.5 mg, or placebo. Episodes of sinus tachycardia associated with an increase of 15 or more beats per minute from baseline occurred in 1.3%, 2.2%, and 0.7% of patients, respectively.[Ref]

Common (1% to 10%): First degree AV block, sinus tachycardia, PR prolongation on ECG
Frequency not reported: Increased heart rate[Ref]

Hypersensitivity

Uncommon (0.1% to 1%): Systemic hypersensitivity including severe urticaria, systemic rash, facial edema, lip swelling[Ref]

Immunologic

In clinical studies 1.6% (n=64) of patients developed anti-drug antibodies (ADAs). Half of the patients had dulaglutide-neutralizing antibodies and half developed antibodies against native GLP-1.[Ref]

Common (1% to 10%): Anti-drug antibodies[Ref]

Local

Common (1% to 10%): Injection site reactions[Ref]

Other

Common (1% to 10%): Fatigue[Ref]

References

1. Cerner Multum, Inc. "Australian Product Information." O 0

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

3. "Product Information. Trulicity (dulaglutide)." Eli Lilly and Company, Indianapolis, IN.

It is possible that some side effects of Trulicity may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide